Back to Browse Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 3

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

Authors Baptist Gallwitz

Published Date May 2010 Volume 2010:3 Pages 117—124

DOI http://dx.doi.org/10.2147/DMSO.S4857

Published 10 May 2010

Baptist Gallwitz

Dept Medicine IV, Tübingen University, Otfried-Müller-Str, 10, 72076 Tübingen, Germany

Abstract: Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes, with a duration profile for once daily dosing. It is highly selective for DPP-4 in comparison to other enzymes of the dipeptidyl peptidase family. DPP-4 inhibitors elevate plasma concentrations of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This effect results in a glucose-dependent stimulation of insulin secretion and an inhibition of glucagon secretion without an intrinsic risk for hypoglycemia. In comparison to sulfonylureas and thiazolidinediones that promote weight gain, DPP-4 inhibitors are weight neutral. Saxagliptin has been approved by the FDA for the US and by the EMEA for Europe in 2009. Clinical trials showed a dose-dependent inhibition of DPP-4 by saxagliptin in doses ranging from 2.5 to 100 mg daily without serious side effects. Type 2 diabetic patients receiving 5 mg to 10 mg saxagliptin once daily had a significant lowering of HbA1c and glycemic parameters along with good tolerability and safety. Saxagliptin has demonstrated a good efficacy for glycemic parameters in various patient populations either in monotherapy or in combination with metformin and other oral antidiabetic drugs as well as a favorable cardiovascular profile. With its high selectivity for DPP-4 and its clinical and cardiovascular profile, saxagliptin is an attractive novel DPP-4 inhibitor.

Keywords: type 2 diabetes, diabetes therapy, DPP-4 inhibitors, incretin based therapy, GLP-1, saxagliptin

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Readers of this article also read:

Osteogenic cell differentiation on H-terminated and O-terminated nanocrystalline diamond films

Liskova J, Babchenko O, Varga M, Kromka A, Hadraba D, Svindrych Z, Burdikova Z, Bacakova L

International Journal of Nanomedicine 2015, 10:869-884

Published Date: 27 January 2015

Ag-plasma modification enhances bone apposition around titanium dental implants: an animal study in Labrador dogs

Qiao SC, Cao HL, Zhao X, Lo HW, Zhuang LF, Gu YX, Shi JY, Liu XY, Lai HC

International Journal of Nanomedicine 2015, 10:653-664

Published Date: 14 January 2015

Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2rγnull mice treated with alogliptin

Jurczyk A, diIorio P, Brostowin D, Leehy L, Yang C, Urano F, Harlan DM, Shultz LD, Greiner DL, Bortell R

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013, 6:493-499

Published Date: 13 December 2013

Morning cortisol is lower in obese individuals with normal glucose tolerance

Praveen EP, Sahoo JP, Kulshreshtha B, Khurana ML, Gupta N, Dwivedi SN, Kumar G, Ammini AC

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011, 4:347-352

Published Date: 7 September 2011

Is vitamin D status a determining factor for metabolic syndrome? A case-control study

Salekzamani S, Neyestani TR, Alavi-Majd H, Houshiarrad A, Kalayi A, Shariatzadeh N, Gharavi A

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011, 4:205-212

Published Date: 10 June 2011

Treating statin-intolerant patients

Arca M, Pigna G

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011, 4:155-166

Published Date: 28 April 2011

Imaging body composition in obesity and weight loss: challenges and opportunities

Heidi J Silver, E Brian Welch, Malcolm J Avison, et al

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010, 3:337-347

Published Date: 28 September 2010

Optimizing the time of doxil injection to increase the drug retention in transplanted murine mammary tumors

Shaojin You, Lian Zuo, Wei Li

International Journal of Nanomedicine 2010, 5:221-229

Published Date: 26 March 2010